









市場行情
/
股票
/
nasdaq-kod
/

Kodiak Sciences Inc

KOD

31.080USD

+3.630+13.22%

收盤 12/24, 13:00（美東）報價延遲15分鐘

1.65B總市值

虧損本益比TTM



Kodiak Sciences Inc

31.080

+3.630+13.22%

概覽公司財務分析

概覽

公司

財務

分析

關於 Kodiak Sciences Inc 公司

Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab tedromer, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy and wet age-related macular degeneration. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate designed to inhibit interleukin-6 (IL-6)-mediated inflammation and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.

Kodiak Sciences Inc簡介



公司代碼KOD

公司名稱Kodiak Sciences Inc

上市日期Oct 04, 2018

CEOPerlroth (Victor)

員工數量109

證券類型Ordinary Share

年結日Oct 04

公司地址1250 Page Mill Rd

城市PALO ALTO

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編94304

電話16502810850

網址https://kodiak.com/

公司代碼KOD

上市日期Oct 04, 2018

CEOPerlroth (Victor)

Kodiak Sciences Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+0.63%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

Dr. Taiyin Yang, Ph.D.

Independent Director

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

Dr. Felix J. Baker, Ph.D.

Independent Director

Dr. Bassil I. Dahiyat, Ph.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. John A. Borgeson

Chief Financial Officer, Executive Vice President, Secretary

183.32K

+0.63%

Mr. Charles A. (Charlie) Bancroft

Independent Director

25.95K

Mr. Robert A. Profusek, J.D.

Lead Independent Director

10.00K

Dr. Richard S. Levy, M.D.

Independent Director

1.00K

Dr. Taiyin Yang, Ph.D.

Independent Director

Dr. Victor Perlroth, M.D.

Chairman of the Board, Chief Executive Officer, Co-Founder

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月17日週一

持股股東

股東類型

持股股東

佔比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.20%

其他

51.15%

持股股東

佔比

Baker Bros. Advisors LP

32.66%

Point72 Asset Management, L.P.

4.65%

Perlroth (Victor D)

4.42%

BlackRock Institutional Trust Company, N.A.

3.93%

The Vanguard Group, Inc.

3.20%

其他

51.15%

股東類型

持股股東

佔比

Hedge Fund

46.39%

Investment Advisor

17.84%

Investment Advisor/Hedge Fund

9.17%

Individual Investor

4.78%

Research Firm

1.78%

Endowment Fund

1.13%

Private Equity

1.04%

Pension Fund

0.16%

Bank and Trust

0.07%

其他

17.64%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

248

41.93M

79.39%

-9.11M

2025Q2

273

46.04M

87.25%

-8.67M

2025Q1

302

46.32M

87.78%

-8.84M

2024Q4

308

44.88M

85.29%

-7.98M

2024Q3

318

42.74M

81.24%

-12.36M

2024Q2

326

43.49M

82.78%

-12.58M

2024Q1

345

46.64M

88.83%

-7.18M

2023Q4

377

44.39M

84.60%

-13.12M

2023Q3

391

45.97M

87.64%

-8.18M

2023Q2

401

46.07M

88.00%

-6.85M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

Baker Bros. Advisors LP

17.31M

32.77%

Jun 30, 2025

Point72 Asset Management, L.P.

452.70K

0.86%

-619.72K

-57.79%

Jun 30, 2025

Perlroth (Victor D)

2.70M

5.1%

+527.00K

+24.31%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

2.69M

5.08%

-148.79K

-5.25%

Jun 30, 2025

The Vanguard Group, Inc.

1.82M

3.45%

+133.49K

+7.90%

Jun 30, 2025

Adage Capital Management, L.P.

2.06M

3.89%

+730.00K

+55.06%

Jun 30, 2025

ICONIQ Capital, LLC

1.27M

2.4%

Jun 30, 2025

TCG Crossover Management, LLC

1.15M

2.17%

Jun 30, 2025

Acadian Asset Management LLC

1.97M

3.73%

+23.74K

+1.22%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Fidelity Enhanced Small Cap ETF

0.18%

iShares Micro-Cap ETF

0.11%

Vanguard US Momentum Factor ETF

0.11%

Invesco RAFI US 1500 Small-Mid ETF

0.06%

iShares Health Innovation Active ETF

0.06%

iShares Russell 2000 Value ETF

0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

0.05%

ProShares Hedge Replication ETF

0.03%

ProShares UltraPro Russell2000

0.03%

Proshares Ultra Russell 2000

0.02%

Fidelity Enhanced Small Cap ETF

佔比0.18%

iShares Micro-Cap ETF

佔比0.11%

Vanguard US Momentum Factor ETF

佔比0.11%

Invesco RAFI US 1500 Small-Mid ETF

佔比0.06%

iShares Health Innovation Active ETF

佔比0.06%

iShares Russell 2000 Value ETF

佔比0.05%

Invesco Russell 2000 Dynamic Multifactor ETF

佔比0.05%

ProShares Hedge Replication ETF

佔比0.03%

ProShares UltraPro Russell2000

佔比0.03%

Proshares Ultra Russell 2000

佔比0.02%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Kodiak Sciences Inc的前五大股東是誰？



Kodiak Sciences Inc的前五大股東如下：
Baker Bros. Advisors LP
持有股份：17.31M
佔總股份比例：32.77%。
Point72 Asset Management, L.P.
持有股份：452.70K
佔總股份比例：0.86%。
Perlroth (Victor D)
持有股份：2.70M
佔總股份比例：5.10%。
BlackRock Institutional Trust Company, N.A.
持有股份：2.69M
佔總股份比例：5.08%。
The Vanguard Group, Inc.
持有股份：1.82M
佔總股份比例：3.45%。